Citizens Reiterates Market Outperform on Spruce Biosciences, Maintains $144 Price Target

Benzinga · 1d ago
Citizens analyst Jonathan Wolleben reiterates Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and maintains $144 price target.